AAP
CMPX icon

Arax Advisory Partners’s Compass Therapeutics CMPX Stock Holding History

Arax Advisory Partners’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.5K Buy
+5,725
New +$16.9K ﹤0.01% 4228
2026
Q1 		– Sell
-18
Closed -$97 – 3899
2025
Q4 		$97 Sell
18
-207
-92% -$956 ﹤0.01% 3828
2025
Q3 		$787 Buy
+225
New +$711 ﹤0.01% 3304

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Arax Advisory Partners's CMPX Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Compass Therapeutics (CMPX) in Q2 2026: 5,725 shares worth $12.5K. The stake represents ﹤0.01% of the portfolio and ranks #4228 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in CMPX as recently as Q4 2025.

Arax Advisory Partners first reported a position in CMPX in Q3 2025 and has held it in 3 quarters since. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Arax Advisory Partners held 5,725 shares of Compass Therapeutics worth $12.5K as of Q2 2026.
  • Compass Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Compass Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4228 holding.
  • Arax Advisory Partners first reported a position in Compass Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.